Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
From major journals, first or last author from the Institute for Cancer Research
Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B(2025) Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes Commun Biol, 8(1), 992 DOI 10.1038/s42003-025-08413-0, PubMed 40610675
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature, 642(8069), 877-888 DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA(2025) Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis J Transl Med, 23(1), 672 DOI 10.1186/s12967-025-06644-7, PubMed 40528241
Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B(2025) Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes Commun Biol, 8(1), 992 DOI 10.1038/s42003-025-08413-0, PubMed 40610675
Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH(2025) Elevated KRAS protein level is associated with better survival in pancreatic cancer BMC Cancer, 25(1), 1080 DOI 10.1186/s12885-025-14461-w, PubMed 40596921
Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C(2025) Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Pharmacoepidemiol Drug Saf, 34(7), e70181 DOI 10.1002/pds.70181, PubMed 40552731